You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥-B(09688.HK):第三季度收入5750萬美元 同比增長33%

格隆匯11月10日丨再鼎醫藥-B(09688.HK)發佈公吿,2022年第三季度收入5750萬美元,同比增長33%,季度環比增長19%,則樂引領銷售收入持續增長 。就TIVDAK®(tisotumab vedotin)達成的區域戰略合作將繼續加強再鼎醫藥在中國女性腫瘤治療領域的領先地位。穩健的資產負債狀況,現金儲備達到11.2億美元。

報吿期內,研發支出為9950萬美元,2021年同期為5510萬美元。研發支出的增加主要是由於第三季度與Seagen簽訂新的許可和合作協議相關的3000萬美元的首付款、正在進行及新啟動的臨牀研究的相關費用的增加、增聘研發人員的工資及工資相關開支以及股權激勵支出增加所致。

再鼎醫藥創始人、董事長兼首席執行官杜瑩博士表示:“再鼎醫藥在第三季度的表現有諸多亮點,我們達成一項與現有產品管線具有高度協同性的新的區域戰略合作,商業化產品均實現穩健的收入增長,在達成2022年的公司重點目標方面也取得了長足進展。隨着我們不斷增加在產品商業化和開發方面的努力,公司在目標疾病領域的戰略定位已經形成強大並有協同效應的平台,惠及大中華區和全球患者。展望未來,我們期望不斷有臨牀後期開發候選產品在關鍵臨牀研究和註冊申請方面取得進展,助力公司繼續發展。例如,我們已與國家藥品監督管理局 (NMPA)就KarXT用於精神分裂症的橋接研究開發計劃達成一致。此外,我們最近宣佈與Seagen就 TIVDAK的許可達成戰略合作,進一步增強了我們解決女性腫瘤領域未滿足醫療需求的能力。 TIVDAK是首個也是目前唯一在美國獲批用於治療復發或轉移性宮頸癌成人患者的抗體偶聯藥物(ADC)。再鼎醫藥正在推進這一產品在中國的關鍵研究。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account